pharmaphorum

NOVEMBER 12, 2020

In 2018, it bought Element Genomics – a spin-out of Duke University in the US – to add genome-editing technologies, and has also been growing its internal exercise at its Boston R&D hub, although so far it hasn’t advanced and gene therapies into clinical development.

Gene Therapy 52

Gene Therapy Gene Manufacturing Contract Manufacturing 52

The Pharma Data

MARCH 1, 2022

A key element of this partnership involves Lifebit’s CloudOS platform – a powerful, secure and cutting-edge platform used by a growing number of research organizations and governments globally, such as Genomics England and The Hong Kong Genome Project. Source link: [link].

Biobanking 52

Biobanking Genome Genomics Genome Project 52

The Pharma Data

NOVEMBER 15, 2020

MultiStem ® cell therapy is a patented regenerative medicine product candidate in clinical development that has shown the ability to promote tissue repair and healing in a variety of ways, such as through the production of therapeutic factors in response to signals of inflammation and tissue damage. About MultiStem ®.

Clinical Trials 40

Clinical Trials Clinical Trials Production Trials 40

The Pharma Data

JUNE 2, 2022

The innovative antibodies from A*STAR can potentially enable the development of safer, more efficacious therapies as they selectively bind to antigens that are highly expressed on tumor cells but are absent on normal healthy tissues. .

Antibody 52

Antibody Licensing Licensing Development 52